April 3, 2023
| Trial | PACIFIC-9 |
|---|---|
| Cancer Type | Lung Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | A Phase III, double-blind, placebo-controlled, Randomized, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients with Locally Advanced (Stage III), Unresectable, Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy |
 |
Click Here to view Cancer Research UK trial summary |